Projects / Programmes
Tromboza in tromboliza (Slovene)
Code |
Science |
Field |
Subfield |
3.06.00 |
Medical sciences |
Cardiovascular system |
|
Code |
Science |
Field |
B530 |
Biomedical sciences |
Cardiovascular system |
B490 |
Biomedical sciences |
Haematology, extracellular fluids |
anticoagulant treatment, antithrombin III, factor V, fibrinogen, fibrinolysis, hemostasis, mutation, polymorphism, protein C, protein S, risk factors, tissue plasminogen activator inhibitor, tissue plasminogen activator, venous thrombosis
Researchers (35)
Organisations (1)
Abstract
Altered fibrinolysis, predominantly due to increased level of tissue plasminogen activator inhibitor and decreased release of plasminogen activators from the vascular wall increases risk for development of cardiovascular diseases. In the studies conducted during in 1998, the effect of various stimuli on the release of tissue plasminogen activator (t-PA) was investigated. It was observed that vazopresine analogue (DDAVP) is probably the only real stimulus for t-PA release. Increase in t-PA during physical activity is probably caused by decreased clearance of t-PA in the liver during exercise. Preliminary results on release of t-PA from the arterial wall suggest that t-PA might be release also from this part of the vasculature.
Genetic factors, leading to alterations of haemostasis are important for the development of venous thromboembolism. Inherited defects of antithrombin III, protein C, protein S and coagulation factor V were studies in families of patients with venous trombosis. It was established that mutation in factor V gene is the most prevalent defect, since it was observed in 11/14 patients and in 12/23 of their close relatives. Antithrombin III defect was observed in 3/14 patients and in 3/11 of their relatives. Plasma fibrinogen concentration, which has an important role for the development of cardiovascular disease, is effected by environmental and genetic factors. Polymorphisms in the gene for alpha (TaqI polymorphism) and beta (HaeIII and BclI polymorphism) fibrinogen chains were studied in apparently healthy Slovenes. It was observed that the latter two polimorphisms affected plasma fibrinogen concentration only in non-smokers. It was presumed that in smokers other mechanisms of fibrinogen regulation prevail over genetic regulation.
Population of patiens with antikoagulant tretament has considerably changed in the last years. Most prevalent are patients with chronic atrial fibrillation, aged over 65 years. The aim was to establish quality of anticoagulant treatment in the elderly patients. It was observed that patients needed lower dose of warfarin, did not bleed more frequently, and needed more time to get into optimal therapeutic range if they were over-anticoagulated.